Date: March 25, 2013 By:
“Decades of research and three large-scale clinical trials have so far failed to yield an effective HIV vaccine, in large part because the virus evolves so rapidly that it can evade vaccine-induced immune responses.
Researchers from the Ragon Institute of Mass General, MIT, and Harvard University have now developed a new approach to vaccine design that may allow them to cut off those evolutionary escape routes. The researchers have developed and experimentally validated a computational method that can analyze viral protein sequences to determine how well different viral strains can reproduce in the body. That knowledge gives researchers an unprecedented guide for identifying viral vulnerabilities that could be exploited to design successful vaccine targets.
The team, led by Arup K. Chakraborty, the Robert T. Haslam Professor of Chemical Engineering, Chemistry, Physics and Biological Engineering at MIT, has designed protein fragments (peptides) that would target these weaknesses. Ragon Institute researchers are now developing ways to deliver the peptides so they can be tested in animals. ”
Read more at MIT News
Image: This scanning electron micrograph shows HIV particles infecting a human T cell. (Source: National Institutes of Health)
A collaborative effort between researchers from Uganda, Tanzania, the US, Spain, and Denmark has resolved a longstanding question in malaria research: Do individuals living in regions with continuous malaria transmission develop broadly neutralizing antibodies (BnAbs) against the malaria parasite? The answer is yes.
Researchers at the Ragon Institute of Mass General Brigham, MIT, and Harvard have uncovered critical insights into how aging impairs the immune system’s ability to fight cancer.
